Market Access NICE to consult on inflation-busting fee increases NICE ran a webinar on 2nd November, setting out – ahead of a formal consultation due to open on 21s
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Articles NICE and Highly Specialised Technologies: three years on Leela Barham examines the process for the appraisal of Highly Specialised Technologies.
News Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
